[Live xenogenic vaccine in the prevention of metastases of uveal melanoma].
By the results of experimental studies and by being guided by Protocol No. 22 dated January 22, 2004, by the Ministry of Health of the Russian Federation, the authors have conducted clinical trials of biotherapy used in oncological care. They describe the first experience in using xenovaccination in 35 patients with uveal melanoma to prevent hematogenic metastases. The follow-ups of the patients lasted within 14-49 months after initiation of the vaccination. No recurrences were observed in 30 patients during follow-ups whose durations averaged 41.3 months. The authors consider that this is reason to regard xenovaccination as an available method for the prevention of metastases of uveal melanoma.
Brovkina
A F
AF
Keshelava
V V
VV
Sologub
V K
VK
Koromyslova
I K
IK
Severin
S E
SE
Barannikova
T V
TV
D000328:Adult; D000368:Aged; D000818:Animals; D019496:Cancer Vaccines / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008545:Melanoma / Q000517:prevention & control / Q000556:secondary*; D051379:Mice; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000517:prevention & control*; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D014604:Uveal Neoplasms / Q000473:pathology* / Q000517:prevention & control
D019496:Cancer Vaccines